Synergic interaction of rifaximin and mutaflor (Escherichia coli Nissle 1917) in the treatment of acetic acid-induced colitis in rats

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Dembiński, Artur ^a   Warzecha, Zygmunt ^a   Ceranowicz, Piotr ^a   Dembiński, Marcin ^a   Cieszkowski, Jakub ^a   Gosiewski, Tomasz ^a   Bulanda, Małgorzata ^a   Kuśnierz Cabala, Beata ^a   Gałazka, Krystyna ^a   Konturek, Peter Christopher ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Teaching Hospital of the University of Jena   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; DNA; ENEMA; MUTAFLOR; MYELOPEROXIDASE; PROBIOTIC AGENT; RIFAXIMIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; COLITIS; COLON BLOOD FLOW; COLON INJURY; COLON MUCOSA; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG POTENTIATION; ENTEROCOCCUS; ENZYME ACTIVITY; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE; HEALING; HISTOPATHOLOGY; INFLAMMATION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME;

EID: 84982815594     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/3126280     Document Type: Article

References (56)

1. W. F. Stenson, S. B. Hanauer, and R. D. Cohen, "Infammatory bowel disease," in Textbook of Gastroenterology, T. Yamada, D. H. Alpers, A. N. Kalloo, N. Kaplowitz, C. Owyang, and D. W. Powell, Eds., pp. 1386-1472, Wiley-Blackwell, Chichester, UK, 5th edition, 2009.
2. D. C. Baumgart, "The diagnosis and treatment of Crohn's disease and ulcerative colitis," Deutsches Ärzteblatt International, vol. 106, no. 8, pp. 123-133, 2009.
3. S. Macfarlane, H. Steed, and G. T. Macfarlane, "Intestinal bacteria and infammatory bowel disease," Critical Reviews in Clinical Laboratory Sciences, vol. 46, no. 1, pp. 25-54, 2009.
4. A. Swidsinski, V. Loening-Baucke, and A. Herber, "Mucosal fora in Crohn's disease and ulcerative colitis-an overview," Journal of Physiology and Pharmacology, vol. 60, no. 6, pp. 61-71, 2009.
5. A. Swidsinski, A. Ladhof, A. Pernthaler et al., "Mucosal fora in infammatory bowel disease," Gastroenterology, vol. 122, no. 1, pp. 44-54, 2002.
6. L. Gerard, K. W. Garey, and H. L. DuPont, "Rifaximin: a nonab-sorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections," Expert Review of Anti-Infective Terapy, vol. 3, no. 2, pp. 201-211, 2005.
7. M. Pimentel, A. Lembo, W. D. Chey et al., "Rifaximin therapy for patients with irritable bowel syndrome without constipation," The New England Journal of Medicine, vol. 364, no. 1, pp. 22-32, 2011.
8. M. Guslandi, "Rifaximin in the treatment of infammatory bowel disease," World Journal of Gastroenterology, vol. 17, no. 42, pp. 4643-4646, 2011.
9. D. Xu, J. Gao, M. Gillilland III et al., "Rifaximin alters intestinal bacteria and prevents stress-induced gut infammation and visceral hyperalgesia in rats," Gastroenterology, vol. 146, no. 2, pp. 484-496.e4, 2014.
10. C. Prantera, H. Lochs, M. Grimaldi, S. Danese, M. L. Scrib-ano, and P. Gionchetti, "Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease," Gastroenterology, vol. 142, no. 3, pp. 473-481, 2012.
11. A. O. Jigaranu, O. Nedelciuc, A. Blaj et al., "Is rifaximin efective in maintaining remission in Crohn's disease?" Digestive Diseases, vol. 32, no. 4, pp. 378-383, 2014.
12. P. Gionchetti, F. Rizzello, A. Ferrieri et al., "Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial," Digestive Diseases and Sciences, vol. 44, no. 6, pp. 1220-1221, 1999.
13. M. Guslandi, M. C. Petrone, and P. A. Testoni, "Rifaximin for active ulcerative colitis," Infammatory Bowel Diseases, vol. 12, no. 4, p. 335, 2006.
14. M. Guslandi, "Saccharomyces boulardii plus rifaximin in me-salamine-intolerant ulcerative colitis," Journal of Clinical Gas-troenterology, vol. 44, no. 5, p. 385, 2010.
15. S. K. Böhm and W. Kruis, "Probiotics: do they help to control intestinal infammation?" Annals of the New York Academy of Sciences, vol. 1072, pp. 339-350, 2006.
16. M. Zwolińska-Wcisło, T. Brzozowski, T. Mach et al., "Are pro-biotics efective in the treatment of fungal colonization of the gastrointestinal tract? Experimental and clinical studies," Journal of Physiology and Pharmacology, vol. 57, no. 9, pp. 35- 49, 2006.
17. D. Rózanska, B. Regulska-Ilow, I. Choroszy-Król, and R. Ilow, "Rola bakterii Escherichia coli szczep Nissle 1917 w chorobach przewodu pokarmowego," Postȩpy Higieny i Medycyny Dóswi-adczalnej, vol. 68, pp. 1251-1256, 2014.
18. A. Altenhoefer, S. Oswald, U. Sonnenborn et al., "Te probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by diferent enteroinvasive bacterial pathogens," FEMS Immunology and Medical Microbiology, vol. 40, no. 3, pp. 223-229, 2004.
19. W. Kruis, E. Schütz, P. Fric, B. Fixa, G. Judmaier, and M. Stolte, "Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis," Alimentary Pharmacology and Terapeutics, vol. 11, no. 5, pp. 853-858, 1997.
20. W. Kruis, P. Frič, J. Pokrotnieks et al., "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as efective as with standard mesalazine," Gut, vol. 53, no. 11, pp. 1617-1623, 2004.
21. B. J. Rembacken, A. M. Snelling, P. M. Hawkey, D. M. Chalmers, and A. T. R. Axon, "Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial," Te Lancet, vol. 354, no. 9179, pp. 635-639, 1999.
22. H. Matthes, T. Krummenerl, M. Giensch, C. Wolf, and J. Schulze, "Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)," BMC Complementary and Alternative Medicine, vol. 10, article 13, 2010.
23. H. A. Malchow, "Crohn's disease and Escherichia coli: a new approach in therapy to maintain remission of colonic Crohn's disease?" Journal of Clinical Gastroenterology, vol. 25, no. 4, pp. 653-658, 1997.
24. B. R. MacPherson and C. J. Pfeifer, "Experimental production of difuse colitis in rats," Digestion, vol. 17, no. 2, pp. 135-150, 1978.
25. P. K. Randhawa, K. Singh, N. Singh, and A. S. Jaggi, "A review on chemical-induced infammatory bowel disease models in rodents," Korean Journal of Physiology and Pharmacology, vol. 18, no. 4, pp. 279-288, 2014.
26. A. Matuszyk, P. Ceranowicz, Z. Warzecha et al., "Obestatin accelerates the healing of acetic acid-induced colitis in rats," Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 2834386, 7 pages, 2016.
27. Z. Warzecha, D. Ceranowicz, A. Dembiński et al., "Ghrelin accelerates the healing of cysteamine-induced duodenal ulcers in rats," Medical Science Monitor, vol. 18, no. 5, pp. BR181-BR187, 2012.
28. Z. Warzecha, P. Ceranowicz, M. Dembinski et al., "Involvement of cyclooxygenase-1 and cyclooxygenase-2 activity in the therapeutic efect of ghrelin in the course of ethanol-induced gastric ulcers in rats," Journal of Physiology and Pharmacology, vol. 65, no. 1, pp. 95-106, 2014.
29. A. Dembinski, Z. Warzecha, P. Ceranowicz, and S. J. Konturek, "Te role of capsaicin-sensitive sensory neurons and nitric oxide in regulation of gastric mucosal growth," Journal of Physiology and Pharmacology, vol. 46, no. 3, pp. 351-362, 1995.
30. P. P. Bradley, D. A. Priebat, R. D. Christensen, and G. Rothstein, "Measurement of cutaneous infammation: estimation of neu-trophil content with an enzyme marker," Journal of Investigative Dermatology, vol. 78, no. 3, pp. 206-209, 1982.
31. J. Vilaseca, A. Salas, F. Guarner, R. Rodríguez, M. Martínez, and J. R. Malagelada, "Dietary fsh oil reduces progression of chronic infammatory lesions in a rat model of granulomatous colitis," Gut, vol. 31, no. 5, pp. 539-544, 1990.
32. D. Maduzia, A. Matuszyk, D. Ceranowicz et al., "The infuence of pretreatment with ghrelin on the development of acetic-acid-induced colitis in rats," Journal of Physiology and Pharmacology, vol. 66, no. 6, pp. 875-885, 2015.
33. T. Gosiewski, D. Salamon, M. Szopa, A. Sroka, M. T. Malecki, and M. Bulanda, "Quantitative evaluation of fungi of the genus Candida in the feces of adult patients with type 1 and 2 diabetes-a pilot study," Gut Pathogens, vol. 6, no. 1, article 43, 2014.
34. M. Pilarczyk-Zurek, A. Chmielarczyk, T. Gosiewski et al., "Possible role of Escherichia coli in propagation and perpetuation of chronic infammation in ulcerative colitis," BMC Gastroenterology, vol. 13, article 61, 2013.
35. H. Ryu, M. Henson, M. Elk et al., "Development of quantitative PCR assays targeting the 16s rRNA genes of Enterococcus spp. and their application to the identifcation of Enterococcus species in environmental samples," Applied and Environmental Microbiology, vol. 79, no. 1, pp. 196-204, 2013.
36. G. Blum-Oehler, S. Oswald, K. Eiteljörge et al., "Development of strain-specifc PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples," Research in Microbiology, vol. 154, no. 1, pp. 59-66, 2003.
37. S. J. Klebanof, "Myeloperoxidase: friend and foe," Journal of Leukocyte Biology, vol. 77, no. 5, pp. 598-625, 2005.
38. K. M. Mullane, R. Kraemer, and B. Smith, "Myeloperoxidase activity as a quantitative assessment of neutrophil infltration into ischemie myocardium," Journal of Pharmacological Methods, vol. 14, no. 3, pp. 157-167, 1985.
39. C. A. Dinarello, "Immunological and infammatory functions of the interleukin-1 family," Annual Review of Immunology, vol. 27, pp. 519-550, 2009.
40. F. W. Leung, K. C. Su, J. M. Pique, G. Tiefn, E. Passaro Jr., and P. H. Guth, "Superior mesenteric artery is more important than inferior mesenteric artery in maintaining colonic mucosal perfusion and integrity in rats," Digestive Diseases and Sciences, vol. 37, no. 9, pp. 1329-1335, 1992.
41. H. Sørbye and K. Svanes, "The role of blood fow in gastric mucosal defence, damage and healing," Digestive Diseases, vol. 12, no. 5, pp. 305-317, 1994.
42. P. Greant, G. Delvaux, and G. Willems, "Infuence of stress on epithelial cell proliferation in the gut mucosa of rats," Digestion, vol. 40, no. 4, pp. 212-218, 1988.
43. P. A. Hall, P. J. Coates, B. Ansari, and D. Hopwood, "Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis," Journal of Cell Science, vol. 107, no. 12, pp. 3569-3577, 1994.
44. S. J. Konturek, A. Dembinski, Z. Warzecha, T. Brzozowski, and H. Gregory, "Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats," Gastroenterology, vol. 94, no. 6, pp. 1300-1307, 1988.
45. S. Beckert, N. Class, F. Farrahi, and S. Coerper, "Growth hormone enhances gastric ulcer healing in rats," Medical Science Monitor, vol. 10, no. 8, pp. BR255-BR258, 2004.
46. Z. Sun, H. Liu, Z. Yang et al., "Intestinal trefoil factor activates the PI3K/Akt signaling pathway to protect gastric mucosal epithelium from damage," International Journal of Oncology, vol. 45, no. 3, pp. 1123-1132, 2014.
47. S. Fiorucci, E. Distrutti, A. Mencarelli, M. Barbanti, E. Palazzini, and A. Morelli, "Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against infammation in a rodent model of colitis," Digestion, vol. 66, no. 4, pp. 246-256, 2002.
48. M. Schultz, U. G. Strauch, H.-J. Linde et al., "Preventive efects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal infammation in two diferent murine models of colitis," Clinical and Diagnostic Laboratory Immunology, vol. 11, no. 2, pp. 372- 378, 2004.
49. S. Sha, B. Xu, X. Kong, N. Wei, J. Liu, and K. Wu, "Preventive efects of Escherichia coli strain Nissle 1917 with diferent courses and diferent doses on intestinal infammation in murine model of colitis," Infammation Research, vol. 63, no. 10, pp. 873-883, 2014.
50. J. Henker, S. Müller, M. W. Laass, A. Schreiner, and J. Schulze, "Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: An open-label pilot study," Zeitschrif fur Gastroenterologie, vol. 46, no. 9, pp. 874-875, 2008.
51. B. Kleessen, A. J. Kroesen, H. J. Buhr, and M. Blaut, "Mucosal and invading bacteria in patients with infammatory bowel disease compared with controls," Scandinavian Journal of Gas-troenterology, vol. 37, no. 9, pp. 1034-1041, 2002.
52. M. Mylonaki, N. B. Rayment, D. S. Rampton, B. N. Hudspith, and J. Brostof, "Molecular characterization of rectal mucosa-associated bacterial fora in infammatory bowel disease," Infammatory Bowel Diseases, vol. 11, no. 5, pp. 481-487, 2005.
53. T. R. Elliott, N. B. Rayment, B. N. Hudspith et al., "Lamina propria macrophage phenotypes in relation to Escherichia coli in Crohn's disease," BMC Gastroenterol, vol. 15, article 75, 2015.
54. E. Vazeille, A. Buisson, M. A. Bringer et al., "Monocyte-derived macrophages from Crohn's disease patients are impaired in the ability to control intracellular adherent-invasive Escherichia coli and exhibit disordered cytokine secretion profle," Journal of Crohn's and Colitis, vol. 9, no. 5, pp. 410-420, 2015.
55. A. M. Petersen, S. I. Halkjær, and L. L. Gluud, "Intestinal colonization with phylogenetic group B2 Escherichia coli related to infammatory bowel disease: a systematic review and meta-analysis," Scandinavian Journal of Gastroenterology, vol. 50, no. 10, pp. 1199-1207, 2015.
56. V. Kothary, E. J. Scherl, B. Bosworth et al., "Rifaximin resistance in Escherichia coli associated with infammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-naphthylamide-inhibitable efux pumps," Antimicrobial Agents and Chemotherapy, vol. 57, no. 2, pp. 811-817, 2013.